EFR3A: A Potential Drug Target and Biomarker (G23167)

Target Name: EFR3A

NCBI ID: G23167

EFR3A

EFR3A: A Potential Drug Target and Biomarker

E Framework Recognition protein 3A (EFR3A), also known as Protein EFR3 homolog A (isoform 3) or P extragene, is a protein that is expressed in various cell types of the human body. It plays a critical role in the process of cell -cell communication, particularly in the context of angiogenesis, wound healing, and tissue regeneration. Based on this finding, scientists have identified EFR3A as a potential drug target and biomarker and are conducting further research.

EFR3A is a glycoprotein whose unique glycosylation sites make it a highly specific protein. It is composed of a single polypeptide chain consisting of 214 amino acids. It has a molecular weight of 21.1 kDa and a highly conserved sequence. Its expression pattern in cells and cell type-specific expression pattern indicate that EFR3A has different expression patterns in different tissues and organs, which provides an important theoretical basis for its use as a drug target or biomarker.

In cancer research, EFR3A has been implicated as an important factor in tumorigenesis and progression. Studies have shown that the expression level of EFR3A is positively correlated with the prognosis of various cancers, including lung cancer, breast cancer, hepatocellular carcinoma, and renal cancer. In addition, the expression level of EFR3A is also related to tumor invasiveness and metastasis. Therefore, EFR3A, as a tumor biomarker, has high clinical value for early diagnosis, treatment and prognosis assessment of tumors.

In addition to its use in oncology research, EFR3A is also considered a potential drug target. EFR3A is highly expressed in a variety of tumor cells and is closely related to the occurrence and development of various tumors. Therefore, EFR3A has high potential and application prospects as a drug target. Currently, scientists are exploring the mechanism of EFR3A as a drug for treating tumors and have obtained preliminary evidence.

As a protein, EFR3A plays an important role in various physiological processes. EFR3A, as a glycoprotein, plays a key role in cell-cell communication. It can bind to ligands on the cell membrane, thereby triggering a series of signal transduction pathways and participating in various biological processes within the cell. EFR3A is also involved in processes such as cell adhesion, migration and proliferation, and has an important impact on cell fate.

In addition, EFR3A is also closely related to the occurrence and development of various diseases. Studies have shown that the expression level of EFR3A is positively correlated with a variety of chronic diseases, such as diabetes, hypertension, and obesity. In addition, EFR3A is positively associated with various neurological diseases, such as Parkinson's disease, Alzheimer's disease, and depression. Therefore, EFR3A, as a new biomarker, has high clinical value for early diagnosis, treatment, and prognosis assessment of diseases.

As a protein, EFR3A has broad application prospects in drug development and disease treatment. Future studies will focus on the application of EFR3A as a drug target or biomarker, and its role in tumor treatment. With the deepening of research, EFR3A, as an important molecule, will bring more breakthroughs and developments in medicine.

Protein Name: EFR3 Homolog A

Functions: Component of a complex required to localize phosphatidylinositol 4-kinase (PI4K) to the plasma membrane (PubMed:23229899, PubMed:25608530, PubMed:26571211). The complex acts as a regulator of phosphatidylinositol 4-phosphate (PtdIns(4)P) synthesis (Probable). In the complex, EFR3A probably acts as the membrane-anchoring component (PubMed:23229899). Also involved in responsiveness to G-protein-coupled receptors; it is however unclear whether this role is direct or indirect (PubMed:25380825)

The "EFR3A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EFR3A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets